The study aims to investigate the impact of preeclampsia on hemostasis.
In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.
Study Type
OBSERVATIONAL
Enrollment
60
Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry
ADP induced platelet aggregation
Time frame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry
Arachidonic acid induced platelet aggregation
Time frame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry
Thrombin induced platelet aggregation
Time frame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
Parameters of plasmatic coagulation system
von Willebrand Factor, Factor VIII, Factor XIII, parameter of conventional coagulation testing (apTT, INR, platelet count, Fibrinogen)
Time frame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.